Released: Last reviewed:
GLP-1 telehealth news ledger
Dated developments that change what GLP-1 telehealth costs or how it can be sold, newest first. Ten entries, September 18 to October 15, 2026. Each links to its primary source; "reported" means a news report we could not confirm in a primary document.
Our October re-read of 20 GLP-1 telehealth providers
We re-read 18 of the 20 providers we profile from their own pages. Eden dropped its membership ($129 tirzepatide, $99 semaglutide a month); Found began printing tirzepatide prices per 28-day cycle; TrimRx and MEDVi pages conflict; Oak Longevity stopped printing per-drug prices. NexLife's standard prices did not change.
What it means if you pay cash: Yearly costs moved by as much as $1,968 for one program. Re-check any quote older than a month.
Source: Full analysis
Medicare Open Enrollment opens; Lilly sets October 29 for third-quarter results
Medicare Open Enrollment runs October 15 to December 7, 2026, with changes effective January 1. Lilly said it will report third-quarter 2026 results on October 29.
What it means if you pay cash: Medicare enrollees who qualify for the GLP-1 Bridge pay $50 a month for three brand drugs. Watch Lilly's results for any change to self-pay Zepbound and Foundayo prices for 2027.
Source: Medicare.gov · Lilly release (syndicated)
Walmart to cover Ozempic and Mounjaro for employees with type 2 diabetes in 2027, not for weight loss
CNBC reports that Walmart will cover more than 250 prescriptions at no cost to employees in 2027, including Ozempic and Mounjaro for type 2 diabetes after prior authorization. The report says Walmart still does not cover Novo or Lilly GLP-1s for weight loss. These details come from news reporting, not a Walmart plan document.
What it means if you pay cash: Employees using a GLP-1 for weight loss stay in the cash-pay market.
Source: CNBC
FDA posts warning letters to two websites selling unapproved injectable semaglutide
Letters 737806 (onlinegenericmedicine.com, dated September 23) and 737810 (cheapmedicineshop.com, dated September 24) say the sites sell unapproved, misbranded semaglutide under names such as "Semanat" and "Semanext".
What it means if you pay cash: "Generic semaglutide" from an online shop is not a low-cost version of Wegovy; FDA treats it as an unapproved drug.
Source: FDA letter 737806 · FDA letter 737810
FDA updates its consumer page on unapproved GLP-1 drugs
The page (current as of October 1) lists telehealth red flags, says to discard compounded multi-dose GLP-1 vials 28 days after first use, warns against semaglutide salt forms and says retatrutide and cagrilintide cannot be used in compounding under federal law. It reports 990 adverse-event reports for compounded semaglutide and more than 730 for compounded tirzepatide as of May 31, 2026.
What it means if you pay cash: A vial sold as an 8–10 week supply may in practice cover 28 days; ask for the beyond-use date.
Source: FDA
Rhode Island Medicaid ends coverage of GLP-1s prescribed only for weight loss
Under the state's fiscal 2027 budget, Rhode Island Medicaid stopped covering Foundayo, Saxenda, Wegovy and Zepbound prescribed solely for weight loss. Coverage continues for type 2 diabetes and other approved uses.
What it means if you pay cash: Affected members move to self-pay or stop treatment.
Source: Tufts Health RITogether notice
CMS: Medicare GLP-1 Bridge runs through December 31, 2027
The CMS BALANCE Model page (modified September 29) says the Medicare GLP-1 Bridge has been extended through December 31, 2027, and includes an FAQ about "the BALANCE Model not launching in Medicare in 2027". Eligible Part D enrollees pay $50 a month for Foundayo, Wegovy or the Zepbound KwikPen.
What it means if you pay cash: People with type 2 diabetes, moderate-to-severe sleep apnea or fatty liver disease are not eligible for the Bridge; their Part D plan might cover a GLP-1.
Source: CMS BALANCE page · Medicare.gov
Federal charges over counterfeit Ozempic distribution
FDA announced that two people were charged with conspiracy and smuggling over counterfeit Ozempic allegedly sourced from China and distributed between July 2023 and April 2024. An indictment is an allegation only.
What it means if you pay cash: Buy brand GLP-1s only through licensed pharmacies, LillyDirect or NovoCare.
Source: FDA
Novo Nordisk: about 90% of Wegovy pill prescriptions are self-pay
Novo's Capital Markets Day presentation says the Wegovy pill has passed 7 million prescriptions this year, about 90% of them self-pay, and describes partnerships with "9+ telehealth entities".
What it means if you pay cash: Self-pay is now the main channel for the Wegovy pill ($149 to $299 a month through NovoCare).
Source: Novo Nordisk
FDA warning letter 738238 to Empower Pharmacy
FDA says Empower's compounded tirzepatide/niacinamide and semaglutide/cyanocobalamin "appear to be essentially copies of FDA-approved semaglutide and tirzepatide products" and cites sterile products "prepared, packed, or held under insanitary conditions". The letter was posted September 22.
What it means if you pay cash: Additive formulations sold by many telehealth programs are the target. Ask which pharmacy fills your prescription.
Source: FDA letter 738238
Still open on October 15, 2026
- 503B bulks list: FDA's April 30, 2026 proposal to keep tirzepatide, semaglutide and liraglutide off the list (91 FR 23431; comments closed July 30, 91 FR 38719) has no final decision yet.
- Retatrutide: Lilly plans to file with FDA in the first quarter of 2027.
- CagriSema: Novo still lists a U.S. decision among its 2026 milestones; none had been announced.
- Brand self-pay: Lilly's savings cards and the reduced Foundayo 2.5 and 5.5 mg prices end December 31, 2026; NovoCare's $199 Wegovy introductory price runs through the same date.